1. In Vivo
  2. >>Deal-Making

Despite Pfizer/Seagen’s Splash, Deals Are Staying Small

First Half 2023 Deal-Making Infographic

 
• By Joseph Haas

Although late 2022 and early 2023 saw a few large transactions, a look at deal activity in the first half of the year shows bolt-on M&A remains in vogue for biopharma. Alliances are down from first half 2022.

Year to year comparison
M&A values are up during H1 2023, but skewed by Pfizer/Seagen • Source: Shutterstock

Biopharmaceutical M&A activity started with a bang in 2023, as Pfizer Inc.’s 13 March acquisition of Seagen Inc.  for $43bn was the sector’s largest buyout since a pair of mega-mergers (Bristol Myers Squibb Company/Celgene Corporation and AbbVie Inc./Allergan plc) in 2019. That deal, combined with Merck & Co., Inc.’s $10.8bn deal for Prometheus Biosciences, Inc on 16 April and on the heels of Amgen, Inc.’s $27.8bn acquisition of Horizon Therapeutics plc announced in December 2022, raised hopes that the industry might see more major transactions. But a look at deal statistics for the first half shows that big pharma by and large remains committed to smaller acquisitions.

The cluster of mega-deals drove up aggregate spending on biopharma M&A, which more than doubled the total spend in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.